Last reviewed · How we verify
Standard CHOP
Standard CHOP is a chemotherapy regimen that combines cyclophosphamide, doxorubicin, vincristine, and prednisone to target rapidly dividing cancer cells.
Standard CHOP is a chemotherapy regimen that combines cyclophosphamide, doxorubicin, vincristine, and prednisone to target rapidly dividing cancer cells. Used for Non-Hodgkin lymphoma, Hodgkin lymphoma.
At a glance
| Generic name | Standard CHOP |
|---|---|
| Sponsor | Japan Clinical Oncology Group |
| Drug class | Chemotherapy regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
The combination of these drugs works synergistically to induce apoptosis in cancer cells, with cyclophosphamide and doxorubicin causing DNA damage, vincristine inhibiting microtubule formation, and prednisone suppressing the immune system's response to the cancer.
Approved indications
- Non-Hodgkin lymphoma
- Hodgkin lymphoma
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Nausea and vomiting
- Fatigue
Key clinical trials
- A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma (PHASE3)
- A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma (PHASE3)
- Geriatric-guided Care Versus Conventional Care in Elderly Unfit/Frail Patients With Diffuse Large B-cell Lymphoma in First Line Treatment (NA)
- Pediatric Acute Respiratory Distress Syndrome (ARDS) Management Trial (PHASE2)
- A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain (PHASE2)
- A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma (PHASE2)
- Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard CHOP CI brief — competitive landscape report
- Standard CHOP updates RSS · CI watch RSS
- Japan Clinical Oncology Group portfolio CI